Sanofi buys China rights to Arrowhead’s lipid drug for $130M upfrontnews2025-08-01T14:47:28+00:00August 1st, 2025|Endpoints News|
FDA chief wants more harmony between CBER and CDERnews2025-07-31T19:48:19+00:00July 31st, 2025|Endpoints News|
Endpoints livestream: Is China’s biotech boom unstoppable?news2025-07-31T14:33:56+00:00July 31st, 2025|Endpoints News|
Ignoring China’s biotech industry is no longer an option. It’s a recipe for disasternews2025-07-31T14:00:23+00:00July 31st, 2025|Endpoints News|
Shanghai biotech VelaVigo snags $60M after landing two licensing dealsnews2025-07-28T11:14:08+00:00July 28th, 2025|Endpoints News|
GSK sends $500M upfront to Hengrui in broad deal with China’s leading pharmanews2025-07-28T08:41:25+00:00July 28th, 2025|Endpoints News|
TCG Labs Soleil gets another $400M for single-asset biotechs, expands to Chinanews2025-07-24T11:00:39+00:00July 24th, 2025|Endpoints News|
Merck’s partner LaNova Medicines is acquired for $951M by Sino Biopharmaceuticalnews2025-07-15T15:04:54+00:00July 15th, 2025|Endpoints News|
Updated: Hengrui plans China filing for obesity shot following pivotal successnews2025-07-15T11:30:39+00:00July 15th, 2025|Endpoints News|
Endpoints livestream: Curie.Bio CEO Zach Weinberg on China biotech competitionnews2025-07-10T11:00:20+00:00July 10th, 2025|Endpoints News|
